anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a method for preparing ultrafine saffron slices, which relates to the field of traditional Chinese medicine processing technology. In the first step, saffron with impurities removed is selected. In the second step, suitable specifications of spare saffron are selected and dried. In the third step, the dried saffron is input into the interior of the feeding tube and heated again through the feeding box. The saffron raw material, which has been crushed twice, enters the crushing chamber. Since the saffron raw material has been preliminarily crushed in advance, the working pressure of the air flow crushing mechanism can be reduced. The preliminary crushing of saffron raw material uses the conveying channel of saffron raw material without additional devices and equipment, reducing the occupied space and production cost. Moreover, it is crushed by air flow. The way, It can preserve the active ingredients in saffron raw materials to the greatest extent possible, and airflow crushing can make the raw materials reach the micrometer level, making them more refined.
Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg IV infusion and docetaxel 60/75/100 mg/m\^2 IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
FIELD: medicine, stomatology. SUBSTANCE: method of treatment of root channel, washing out inflammation focus in periodontium and as curative endodontic bandage in intermediate therapeutic stages involves the use of N-acetyl-L-cysteine. This agent is able to bind arsenic compounds, to liquefy inflammatory exudates and to promote to its evacuation from periodontium tissues. The proposed agent ensures to arrest acute suppurative inflammation in apical periodontium caused by arsenous acid. Invention can be used for treatment of acute arsenous periodontitis. EFFECT: enhanced effectiveness of agent and treatment. 1 tbl
The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.
INTRODUCTION: Following amputation, peripheral nerves lack distal targets for regeneration, often resulting in symptomatic neuromas and debilitating neuropathic pain. Animal models can establish a practical method for symptomatic neuroma formation for better understanding of neuropathic pain pathophysiology through behavioral and histological assessments. We created a clinically translatable animal model of symptomatic neuroma to mimic neuropathic pain in patients and assess sexual differences in pain behaviors.
METHODS: Twenty-two male and female rats were randomly assigned to one of two experimental groups: (1) neuroma surgery, or (2) sham surgery. For the neuroma experimental group, the tibial nerve was transected in the thigh, and the proximal segment was placed under the skin for mechanical testing at the site of neuroma. For the sham surgery, rats underwent tibial nerve isolation without transection. Behavioral testing consisted of neuroma-site pain, mechanical allodynia, cold allodynia, and thermal hyperalgesia at baseline, and then weekly over 8 weeks.
RESULTS: Male and female neuroma rats demonstrated significantly higher neuroma-site pain response compared to sham groups starting at weeks 3 and 4, indicating symptomatic neuroma formation. Weekly assessment of mechanical and cold allodynia among neuroma groups showed a significant difference in pain behavior compared to sham groups (p < 0.001). Overall, males and females did not display significant differences in their pain responses. Histology revealed a characteristic neuroma bulb at week 8, including disorganized axons, fibrotic tissue, Schwann cell displacement, and immune cell infiltration.
CONCLUSION: This novel animal model is a useful tool to investigate underlying mechanisms of neuroma formation and neuropathic pain.
A computer-implemented method of assembling a medical treatment plan for a patient. The method includes presenting, by a computer system, a first treatment option and a second treatment option. At the computer system, receiving a first selection of the first treatment option and receiving a second selection of the second treatment option. With the computer system, generating as a function of the received first selection of the first treatment option and the received second selection of the second treatment option, the medical treatment plan for the patient. In the computer system, storing the medical treatment plan for the patient. The first treatment option and the second treatment option are presented in an order corresponding to a pre-determined medical relationship between the first treatment option and the second treatment option.
For this study data will be collected using self-report questionnaires for the long-term outcome (e.g functional status) and several covariates (e.g., cognition, anxiety and depression, PTSD, QOL, general symptoms, frailty). To retrieve baseline data from prior ICU admission, family members will be used as proxy reporters at inclusion. During treatment in the ICU, patients will be mapped for 5 pre-selected symptoms every day for 7 days, or until death or ICU discharge. Several clinical variables (e.g., SOFA score, pain score, level of sedation, mobilization, medication, mouth care) will be collected daily until maximum 7 days. Follow-up data will be collected at 3, 6 and 12 months after ICU admission using self-report questionnaires.

The predictive value of pre-morbid condition prior to ICU admission on functional status during the first year after an ICU admission will be investigated, when controlled for various clinical and demographic variables. As a secondary analyses, the present study will identify both the occurrence of symptoms as well as the severity and distress of each symptom, while in the ICU. Another secondary outcome that will be measured in this longitudinal study is the association between cognitive function one year after an ICU admission and various mental health variables (PTSD, anxiety and depression).
Despite growing recognition, neuropsychiatric diseases associated with infections are a major unsolved problem worldwide. Group A streptococcal (GAS) infections can cause autoimmune sequelae characterized by movement disorders, such as Sydenham chorea, and neuropsychiatric disorders. The molecular mechanisms underlying these diseases are not fully understood. Our previous work demonstrates that autoantibodies (AAbs) can target dopaminergic neurons and increase dopamine D2 receptor (D2R) signaling. However, AAb influence on dopamine D1 receptor (D1R) activity is underexplored. We found evidence that suggests GAS-induced cross-reactive AAbs promote autoimmune encephalitis of the basal ganglia, a region of high dopamine receptor density. Here, we report a mechanism whereby neuropsychiatric syndromes are distinguished from movement disorders by differences in D1R and D2R AAb titers, signaling, receiver operating characteristic curves, and immunoreactivity with D1R and D2R autoreactive epitopes. D1R AAb signaling was observed through patient serum AAbs and novel patient-derived monoclonal antibodies (mAbs), which induced both D1R G protein- and β-arrestin-transduced signals. Furthermore, patient AAbs and mAbs enhanced D1R signaling mechanisms mediated by the neurotransmitter dopamine. Our findings suggest that AAb-mediated D1R signaling may contribute to the pathogenesis of neuropsychiatric sequelae and inform new options for diagnosis and treatment of GAS sequelae and related disorders.
The use of alprazolam in pregnancy can adversely affect maternal and neonatal health. This study examined neonatal outcomes following exposure to alprazolam in pregnancy. Women prescribed alprazolam during pregnancy (n = 48) between 2014 and 2018 were identified from routinely-collected state administrative prescribing records and perinatal data. Two comparison groups of women; 1) prescribed alprazolam outside of pregnancy (n = 96) and 2) women never prescribed alprazolam (n = 96) were also identified. The health of women and their children was examined using administrative hospital, mortality and perinatal data and compared to the comparison groups using generalized linear models. Prenatal alprazolam exposure was not associated with a reduction in average birth weight or gestational age. However, neonates prenatally exposed to alprazolam were more likely be classified as having low birth weight for gestational age compared with alprazolam comparison group (OR: 4.46, 95% CI: 1.54-12.95) and the non-alprazolam comparison group (OR: 3.27, 95% CI: 1.22-8.79). There were no cases of perinatal mortality or floppy baby syndrome in alprazolam-exposed neonates. While the use of alprazolam during pregnancy was not associated with an increased risk of severe adverse neonatal outcomes (e.g. perinatal mortality), it was associated with neonates being born with a low birth weight for gestational age.
PURPOSE: To obtain a cosmetic for the body excellent in extensibility and refreshingness in coating and further preventing and recovering effects on acne vulgaris by blending a prescribed amount of a semisolid and/or a liquid substances such as liquid paraffin or vaseline in a system consisting essentially of sulfur and zinc oxide. CONSTITUTION: This cosmetic for the body is obtained by adding <=2wt.% semisolid and/or liquid substances to a system consisting essentially of sulfur and zinc oxide. In this cosmetic, the content of the blended sulfur is preferably 0.1-2wt.% and that of the blended zinc oxide is preferably 0.1-10wt.%. The cosmetic for the body is especially effective in preventing and recovering acne vulgaris. For example, a liquid and/or a semisolid oily ingredient such as liquid paraffin, vaseline, squalane or a silicone oil, a humectant such as glycerol, 1,3-butylene glycol or dipropylene glycol and a surfactant, etc., such as a sorbitan ester of a fatty acid or a polyoxyalkylene ether are cited as the semisolid and/or liquid substances.  A low-viscosity oil having <=50cSt viscosity at ambient temperature is especially preferred as the semisolid and/or liquid substances in aspects of a dry feeling of use and preventing effects on the acne vulgaris.
PURPOSE: The study aimed to identify parameters that could predict oncological and functional outcomes in patients with pT4aN0 laryngeal squamous cell carcinoma (LSCC) who underwent open partial horizontal laryngectomy (OPHL). The role of paratracheal neck dissection (PTND) was analyzed as the primary outcome. Additionally, the study compared the outcomes of patients who underwent postoperative radio/chemotherapy (PORT/PORCT) with those who refused or did not adhere to adjuvant treatments.
METHODS: Twenty-nine OPHL patients whose pathological exam was consistent with pT4aN0-x disease were enrolled and their clinical charts were retrospectively reviewed. The study analyzed oncological outcomes, such as local, regional, and distant recurrence rates (RR), overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS). Additionally, functional results were analyzed, including decannulation rate, hospitalization time, and postoperative complication rate.
RESULTS: The study revealed and overall recurrence rate of 27%. The final rates for OS and DSS were 68% and 79%, respectively. Based on the univariate analysis the PTND was significantly associated with longer DFS. No significant differences inoncological outcomes were observed between pT4a patients who underwent adjuvant radio/radiochemotherapy and those who did not, in terms of RR, DFS, DSS or OS. However, adjuvant treatment was found to significantly increase decannulation time.
CONCLUSIONS: In a properly super-selected subgroup of patients with pT4aN0 LSCC, OPHL may beconsidered as a conservative surgical option even without adjuvant treatment. However, for optimal oncological outcomes, it is strongly recommended to consider a central compartment dissection in cases of hypoglottic and anterior extra-laryngeal tumor extension.
Cases of thrombotic microangiopathy (TMA) were reported to occur generally within the first two weeks after ZOLGENSMA infusion in the post-marketing setting [see Adverse Reactions (6.3)]. TMA is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury. Concurrent immune system activation (e.g., infections, vaccinations) was identified in some cases. 

Prompt attention to signs and symptoms of TMA is advised, as TMA can result in life-threatening or fatal outcomes.

Monitor platelet counts closely within the first two weeks following infusion and on a regular basis afterwards [see Warnings and Precautions (5.3)], as well as signs and symptoms of TMA, such as hypertension, increased bruising, seizures, or decreased urine output. In case these signs and symptoms occur in the presence of thrombocytopenia, further diagnostic evaluation for hemolytic anemia and renal dysfunction should be promptly undertaken. If clinical signs, symptoms and/or laboratory findings consistent with TMA occur, consult a pediatric hematologist and/or pediatric nephrologist immediately to manage TMA as clinically indicated.
According to most literature, clients with ALS in general, get few pressure injuries. At this clinic, however, potentially due to the longer life expectancy of clients who choose tracheostomy with mechanical ventilation and a feeding tube, some clients do get pressure injuries. Also, many clients once they are sitting most of the day, whether in the wheelchair, recliner or bed, complain of discomfort and pain. Most clients will use or require a power wheelchair for mobility and positioning in the course of the disease process, and many will require it full time as symptoms progress. Generally, decreased sensation is not a symptom of ALS, but it is unknown why some people with ALS have pain and pressure injuries despite the intact sensation needed to cue repositioning.

It is best clinical practice to provide clients with ALS power wheelchairs that tilt, recline, and have leg elevation for maximal pressure management and to encourage repositioning to reduce the risk of skin breakdown/pressure injury as well as decrease pain. This study will study the effect of having an alerting/coaching system for training and reminders on performing pressure relief and repositioning for decreasing the number of pressure injuries as well as decreasing pain. The VSC also gives contextual cues to achieve a specific angle set-up by the clinician. Not only does the VSC provide alerts, but the client and clinician can observe and track the amount of time the chair is on and in what position.
The present disclosure provides a new and innovative medical wristband that can be thermally printed with patient identification features and that also includes location-tracking features. The provided medical wristband includes a wristband component and a separate closure component. The wristband component may be thermally printed using conventional thermal printers because it is not physically attached to the location tracker that would otherwise make the medical wristband too thick for conventional thermal printers. The wristband component may be printed with patient identification information and/or a scannable code accessing patient identification information. The closure component has a location tracker coupled to it, such as a Bluetooth beacon. In one example, the location tracker is welded to the closure component. Accordingly, a patient may wear a single thermally printed wristband that provides medical professionals with both patient identification features and location tracking features.
Women will receive three tablets of letrozole(FemaraR, NOVARTIS) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
Adverse reaction information concerning PROVENTIL® HFA Inhalation Aerosol is derived from a 12-week, double-blind, double-dummy study which compared PROVENTIL HFA Inhalation Aerosol, a CFC 11/12 propelled albuterol inhaler, and an HFA-134a placebo inhaler in 565 asthmatic patients. The following table lists the incidence of all adverse events (whether considered by the investigator drug related or unrelated to drug) from this study which occurred at a rate of 3% or greater in the PROVENTIL HFA Inhalation Aerosol treatment group and more frequently in the PROVENTIL HFA Inhalation Aerosol treatment group than in the placebo group. Overall, the incidence and nature of the adverse reactions reported for PROVENTIL HFA Inhalation Aerosol and a CFC 11/12 propelled albuterol inhaler were comparable. 

Adverse events reported by less than 3% of the patients receiving PROVENTIL HFA Inhalation Aerosol, and by a greater proportion of PROVENTIL HFA Inhalation Aerosol patients than placebo patients, which have the potential to be related to PROVENTIL HFA Inhalation Aerosol include: dysphonia, increased sweating, dry mouth, chest pain, edema, rigors, ataxia, leg cramps, hyperkinesia, eructation, flatulence, tinnitus, diabetes mellitus, anxiety, depression, somnolence, rash. Palpitation and dizziness have also been observed with PROVENTIL HFA Inhalation Aerosol. 

Adverse events reported in a 4-week pediatric clinical trail comparing PROVENTIL HFA Inhalation Aerosol and a CFC 11/12 propelled albuterol inhaler occurred at a low incidence rate and were similar to those seen in the adult trials. 

In small, cumulative dose studies, tremor, nervousness, and headache appeared to be dose related. 

Rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema have been reported after the use of inhaled albuterol. In addition, albuterol, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vertigo, central nervous system stimulation, insomnia, headache, and drying or irritation of the oropharynx.
The invention discloses application of benzo-fused six-membered heterocyclic compounds to prepare anti-HIV-1 medicines. The general formula of the compounds is shown in the specification. In the general formula, R is a group possessing a carbamide group and possessing no more than 15 carbon atoms and is at one position of No. 1-4 positions; R' is H or a C1-C3 chain hydrocarbon; and X is C, O, N or S. By utilizing the interaction of Vif-APOBEC3G, the compounds with the above general formula, especially the benzo-fused six-membered heterocyclic compounds are confirmed to be capable of inhibiting the activity of Vif protein on degrading A3G and leading rising up of expression level of green fluorescent protein in a screening system. By performing wild-type HIV-1 infection experiments on human primary CD4+T lymphocyte and H9, SupT1 and other CD4+T lymphocytic series, the benzo-fused six-membered heterocyclic compounds are further confirmed to have relatively good antiviral effect. A powerful theoretical basis and a practice basis are provided for further research and development of antiviral medicines, and the compounds have important value on research and development and exploitation meaning.
Sodium ferric gluconate complex in sucrose injection may cause clinically significant hypotension. Hypotension associated with lightheadedness, malaise, fatigue, weakness or severe pain in the chest, back, flanks, or groin has been reported. These hypotensive reactions may or may not be associated with signs and symptoms of hypersensitivity reactions and usually resolve within one to two hours. In the single-dose safety study, postadministration hypotensive events were observed in 22/1,097 patients (2%) following sodium ferric gluconate complex in sucrose injection administration. Transient hypotension may occur during dialysis. Administration of sodium ferric gluconate complex in sucrose injection may augment hypotension caused by dialysis. Monitor patients for signs and symptoms of hypotension during and following sodium ferric gluconate complex in sucrose injection administration [see Adverse Reactions (6.1)].
Cancer cachexia is a prevalent and often fatal wasting condition that cannot be fully reversed with nutritional interventions. Muscle atrophy is a central component of the syndrome, but the mechanisms whereby cancer leads to skeletal muscle atrophy are not well understood. We performed single-nucleus multi-omics on skeletal muscles from a mouse model of cancer cachexia and profiled the molecular changes in cachexic muscle. Our results revealed the activation of a denervation-dependent gene program that upregulates the transcription factor myogenin. Further studies showed that a myogenin-myostatin pathway promotes muscle atrophy in response to cancer cachexia. Short hairpin RNA inhibition of myogenin or inhibition of myostatin through overexpression of its endogenous inhibitor follistatin prevented cancer cachexia-induced muscle atrophy in mice. Our findings uncover a molecular basis of muscle atrophy associated with cancer cachexia and highlight potential therapeutic targets for this disorder.
The phase I portion of the study is a standard dose-escalation schemed designed to determine the maximum tolerated dose (MTD) of cladribine in the combination of bortezomib, cladribine, and rituximab therapy. The MTD is defined as the dose level in which ≤1 out of 6 patients have dose-limiting toxicity (DLT). Rituximab 375 mg/m2 on day 5,12, 19, 26 for 1st cycle, then day 5 of cladribine for next 5 cycles and then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days 1-5 for 6 cycles. Bortezomib 1.6 mg/m2 sub Q days 12,19,26 for 3 cycle, then every 2 weeks maintenance dose until toxicity or progression.
The participants who are allocated to the waiting list control group will receive usual care. They will receive the MBCT intervention 3 months after the intervention group complete their MBCT programme.
An uninterruptible power supply for a medical administration appliance is specified. The power supply has a first energy source (210) and a rechargeable second energy source (120). A first current path (SP 1) is used to route energy from the rechargeable second energy source to a load (110). A second current path (SP 2) with a charging circuit (230) is used to route energy from the first energy source to the second energy source and thereby to charge the second energy source. In the normal mode, the load is supplied with energy essentially via the first current path from the rechargeable second energy source and the second energy source is charged via the second current path from the first energy source. A third current path (SP 3) from the first energy source to the load is designed to supply energy to the load from the first energy source in the event of failure of the second energy source or in the event of a reduced power output from the second energy source in an emergency mode.
Method of manufacture of pharmaceutical compositions in the form of a table containing acetisalicilic acid, in which a delayed release of the therapeutic agent is obtained. Consisting in mixting intimamently of 90.9 to 98 per 100 in the weight of acetilsalicilico acid as a therapeutic agent with 1.0 to 7.5 per 100 in weight of an agent activator of the erosion. The mixture is granulated using a solution of 0.8 to 1.6 per 100 by weight of a control agent of the release in an organic solvent. Drying through the granulated mass and compressing in the form of pills. Cellulose acetate-phthalate is preferred as a release control agent and maize starch as an agent activator of erosion. (Machine-translation by Google Translate, not legally binding)